PPARG and Jeune syndrome: Pharmaceutical approaches, including treatment with peroxisome proliferator-activated receptor γ (PPARγ) agonists like troglitazone, efficiently improve ATD by decreasing visceral and increasing subcutaneous fat [29, 30].